FLATEXDEGIRO-AG
19.5.2022 09:41:12 CEST | Business Wire | Press release
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest growing retail online broker and Boerse Stuttgart Group, Europe's sixth largest exchange group, today announced the signing of a Memorandum of Understanding (MoU) on a partnership in crypto trading. This will give flatexDEGIRO customers direct access to trading in major cryptocurrencies via convenient and direct in-app access from flatex and DEGIRO with an accelerated onboarding process. For this purpose, Boerse Stuttgart Group provides its integrated offer in the crypto business, with uncomplicated trading via the retail platform BISON and use the secure crypto custody service operated by the custodian blocknox. The aim is to launch first at flatex Germany and Austria by the end of the third quarter of 2022, followed by the expansion of the offer to all DEGIRO customers.
Frank Niehage, CEO of flatexDEGIRO: "As the European market leader in online stock trading, cryptocurrencies add a key element to our already very broad product range. Together with the Robo-Advisory offering planned for summer 2022 via our partner Whitebox, flatexDEGIRO will offer its customers the most comprehensive product range of all European online brokers. For us, taking this step with such a renowned and trustworthy partner as Boerse Stuttgart Group was an indispensable requirement for the sustainable protection of our customers, especially in such a young and volatile asset class as cryptocurrencies."
"As the leading European exchange group in the crypto sector, we are pleased to have gained the leading European online broker flatexDEGIRO as a partner. The partnership is part of our strategy to continue to grow as a regulated and integrated provider of crypto services, in both the retail and institutional markets," said Dr Matthias Voelkel, CEO of Boerse Stuttgart Group.
Muhamad Chahrour, CFO of flatexDEGIRO and CEO of DEGIRO: "flatexDEGIRO enables more than 300 million Europeans to take control of their financial future with easy and secure access to the capital market - without restrictions or lazy compromises. Thanks to our technical edge, we offer our customers the broadest product range in the industry on one of the most convenient and stable platforms – at the lowest prices, especially in the most important European growth markets."
"Our partnership with flatexDEGIRO creates enormous added value for customers: They benefit from easy processes, attractive transaction costs and custody of cryptocurrencies free of charge. We can jointly unlock new investor groups and serve their growing interest in digital assets," explains Dr Ulli Spankowski, Chief Digital Officer of Boerse Stuttgart Group and Head of BISON.
Customers can trade the cryptocurrencies Bitcoin, Ethereum, Litecoin, Ripple, Bitcoin Cash, Chainlink and Uniswap on BISON free of charge – 24 hours a day, seven days a week. The admission of further cryptocurrencies will follow in the next months. Only the spread between the displayed buying and selling prices is charged. There are no additional costs for customers, for example for deposits or withdrawals of cryptocurrencies. blocknox GmbH, a subsidiary of Boerse Stuttgart Group, takes care of the custody of cryptocurrencies on an escrow basis. For this purpose, blocknox GmbH has implemented a multi-level security concept.
For further information please contact:
Press contact flatexDEGIRO:
Achim Schreck Phone +49 (0) 69 450001 0
Head of IR & Corporate Communications achim.schreck@flatexdegiro.com
Press Contact Boerse Stuttgart Group:
Johannes Frevert Phone + 49 711 222 985-711
Media Spokesperson johannes.frevert@boerse-stuttgart.de
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates a leading and fastest growing online brokerage platform in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge as well as the high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering to customers, including commission-free brokerage.
With more than 2 million customer accounts and over 91 million securities transactions processed in 2021, flatexDEGIRO is the largest retail online broker in Europe. In times of bank consolidation, low interest rates and digitalisation, flatexDEGIRO is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to expand its customer base to 7- 8 million customer accounts and process 250-350 million transactions per year - even in years of low volatility.
Further information at https://www.flatexdegiro.com/de
About Boerse Stuttgart Group
Boerse Stuttgart Group is the sixth largest exchange group in Europe with strategic pillars in the capital markets business and in the digital and crypto business. It operates exchanges in Germany, Sweden and Switzerland. As a true pioneer, it has built the largest digital and crypto business of all the European exchange groups. Boerse Stuttgart has a workforce of 650 and premises in Stuttgart, Berlin, Stockholm, Zurich and Ljubljana.
Further information at https://www.boerse-stuttgart.de
| Language: | English |
| Company: | flatexDEGIRO AG |
| Rotfeder-Ring 7 | |
| 60327 Frankfurt / Main | |
| Germany | |
| Phone: | +49 (0) 69 450001 0 |
| E-mail: | ir@flatexdegiro.com |
| Internet: | www.flatexdegiro.com |
| ISIN: | DE000FTG1111 |
| WKN: | FTG111 |
| Indices: | SDAX |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1356185 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom